RLYB332

Many patients with severe anemias experience ineffective erythropoiesis (red blood cell production) and iron overload, which are inadequately treated by the current standard of care. These diseases include hereditary hemochromatosis, polycythemia vera, myelodysplastic syndrome, beta thalassemia, and sickle cell anemia. Significant morbidity and mortality can result, including multiorgan damage.   

In addition, there is potential to treat a broader range of iron overload disorders in indications where iron accumulation can have a negative impact such as osteoporosis, post-menopausal iron overload diseases, cirrhosis, cardiomyopathy, and diabetes.

RLYB332 is a long-acting monoclonal anti-matriptase-2 antibody that is designed to inhibit MTP-2 thereby increasing levels of hepcidin, a key protein regulator of iron in the circulation